Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
SAN FRANCISCO, Dec. 22, 2016 -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
iRhythm’s management is scheduled to present on Wednesday, January 11, 2017 at 11:00am PT. Interested parties may access a webcast of the presentation on the “Investor Relations” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a commercial-stage digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients. The company’s platform, the Zio Service, has been provided to over 500,000 patients, accumulating more than 125 million hours of curated heartbeat data within iRhythm’s data repository.
Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 [email protected] Media Contact Aaron Murphy (415) 229-3331 [email protected]
